1-{3-[(2,5-Dioxopyrrolidin-1-Yl)Oxy]-3-Oxopropyl}-1H-Pyrrole-2,5-Dione

When SMP is used to conjugate amine-bearing chemotherapeutics to pre-thiolated PLGA nanoparticles for passive tumor targeting, what process variables determine ligand density and colloidal stability?

Poly(lactic-co-glycolic acid) nanoparticles (140–220 nm intended hydrodynamic diameter) are first surface-modified by incorporating a thiol-terminated poly(ethylene glycol)-PLGA block copolymer via nanoprecipitation from acetone into aqueous 0.3% w/v Pluronic F-68, purified by tangential flow filtration on a 300 kDa MWCO mPES membrane cassette. Thiol surface density is quantified using a modified Ellman’s reagent assay (DTNB, 5,5′-dithiobis(2-nitrobenzoic acid)) against a cysteine standard curve, with a target of 45–70 nmol free thiol per mg of nanoparticle. SMP is dissolved in anhydrous DMF immediately before use to avoid pre-hydrolysis and added to the nanoparticle suspension at a maleimide-to-thiol molar ratio ranging from 1.2:1 to 5:1; the reaction proceeds at 20 °C under nitrogen for 60 minutes, after which unreacted maleimide is quenched with 5 mM L-cysteine. The NHS ester-functionalized intermediate is recovered by centrifugation at 18,000× g for 30 minutes and resuspended in 100 mM HEPES buffer at pH 7.0. An amine-containing active pharmaceutical ingredient—such as doxorubicin modified with a short ethylene diamine spacer—is then introduced at 2.5 equivalents relative to NHS ester and incubated for 2 hours; purification is achieved by size-exclusion chromatography on Sepharose CL-4B to remove unconjugated drug and low-molecular-weight reaction byproducts. The colloidal integrity of the final conjugate is assessed by dynamic light scattering at 173° backscatter detection on a Malvern Zetasizer Nano ZS, and a 10% increase in polydispersity index beyond 0.15 is cause for batch rejection. SMP-mediated conjugation characteristically shifts the zeta potential by +3 to +8 mV depending on the amine payload pKa, and in vitro release kinetics in pH 5.0 acetate buffer at 37 °C show an initial burst of <15% payload within 24 hours if SMP hydrolysis products act as plasticizers. Long-term lyophilized storage stability requires a residual moisture content of <1.5% determined by Karl Fischer titration, and redispersion must recover a particle size within 110% of the original value per ISO 22412:2017.

Maleimide ring hydrolysis during ambient-temperature aqueous conjugation: a kinetic limitation that reshapes process windows

In all applications of SMP, the competition between thiol addition and maleimide ring-opening to maleamic acid represents the single most critical control point, directly affecting crosslinking efficiency and product homogeneity. The rate constant for maleimide hydrolysis in 100 mM phosphate buffer at 25 °C has been reported as k = 0.009 min⁻¹ at pH 7.0, rising to k = 0.045 min⁻¹ at pH 8.0, with the reaction exhibiting a first-order dependence on hydroxide ion concentration; this implies that the half-life of the maleimide group shortens from roughly 77 minutes to 15 minutes across this 1.0-unit pH span. Consequently, in typical bio-conjugation workflows where the desired reaction is the thiol-maleimide Michael addition, process engineers intentionally suppress pH to 6.5–6.8 to preserve the electrophilic double bond, even though the thiolate nucleophile population is reduced, extending the required reaction time to 1.5–2 hours. The trade-off is further complicated by the fact that the NHS ester on the opposite terminus hydrolyzes more rapidly above pH 7.5, with a half-life of approximately 4 hours at pH 7.0 and 2.5 hours at pH 7.5; thus, the simultaneous integrity of both reactive groups is maximized in a narrow operational band between pH 6.8 and 7.2. An additional layer of complexity is the susceptibility of the succinimidyl thioether adduct to undergo retro-Michael elimination at pH >7.4 in the presence of competing nucleophiles such as glutathione (2–10 mM in intracellular environments), releasing maleimide and regenerating free thiol; the equilibrium constant for this retro-reaction has been measured to yield 2–5% dissociation within 24 hours under physiologically relevant conditions, undermining the stability of ADCs and targeted delivery systems. To suppress this pathway, post-conjugation treatment with 20 mM N-ethylmaleimide is sometimes applied to cap residual free thiols, although this secondary modification must be carefully documented under ICH Q8(R2) quality-by-design frameworks. Real-time monitoring of maleimide consumption by inline UV spectroscopy at 300 nm (where the maleimide chromophore absorbs) integrated onto an ÄKTA pure chromatography system offers a direct measure of reaction progress, avoiding the artefacts induced by post-reaction quenching. In validated manufacturing processes, the acceptable maleimide hydrolysis byproduct content is typically set below 5% of total linker-derived species, verified by LC-MS with extracted ion chromatograms, a limit aligned with USP <1043> guidance on ancillary materials for biologics.

Enzyme immobilization onto thiol-activated screen-printed electrodes via an SMP heterobifunctional strategy for amperometric detection of clinical biomarkers

Screen-printed carbon electrodes are first electrochemically pretreated by cycling between -0.5 V and +1.2 V in 0.5 M H₂SO₄ to introduce carboxylate functional groups, followed by activation with 50 mM EDC and 25 mM sulfo-NHS in 50 mM MES buffer at pH 6.0 for 45 minutes, generating semi-stable amine-reactive NHS esters on the surface. A thiol-containing spacer such as cysteamine dihydrochloride is then grafted at 200 mM in pH 7.2 PBS for 2 hours, irreversibly installing free sulfhydryl groups. SMP is dissolved in anhydrous DMSO to a concentration of 10 mM and dropped onto the electrode surface in a humidified chamber purged with argon; the maleimide portion anchors to the exposed thiols during a 30-minute incubation, while the NHS ester projects outward for enzyme capture. The target oxidoreductase—glucose oxidase or cholesterol oxidase commonly—is exchanged into 10 mM phosphate buffer at pH 7.8 by centrifugal ultrafiltration (10 kDa MWCO) and applied to the activated electrode at 1 mg/mL for 1 hour, coupling via solvent-accessible lysine residues. Residual active NHS groups are deactivated with 1 M ethanolamine at pH 8.5 for 15 minutes. The biosensor’s performance is characterized by cyclic voltammetry at a scan rate of 50 mV/s in 5 mM ferri/ferrocyanide redox mediator; a decrease in peak current upon analyte addition is indicative of H₂O₂-mediated competition. The apparent Michaelis constant K_m^app typically shifts from 3.2 mM for the free enzyme to 7.8 mM when SMP-immobilized on the electrode, reflecting diffusional constraints, and the current density at substrate saturation reaches 12–18 μA/cm² for a cholesterol oxidase film with an enzyme loading of 4.2 μg per electrode (determined by Bradford assay after alkaline desorption). A recognized incompatibility is the gradual desorption of thiol-bound conjugate from gold nanoparticle-modified electrodes in the presence of chloride ions above 50 mM, which compete for Au-S binding; inclusion of a dithiol under-layer such as α-lipoic acid reduces signal drift to <1.2% over 8 hours. Shelf-life under dry storage at 4 °C is specified as 6 months with less than 10% loss of initial activity, and inter-electrode CV determined on 6 replicates must not exceed 8% to pass system suitability criteria adapted from ISO 15197:2013 for glucose test systems.

In the development of radio-metal-chelate-bearing peptides for positron emission tomography, the amine-reactive NHS ester of SMP is exploited to introduce a macrocyclic chelator such as DOTA-NHS ester or NOTA-NHS to the ε-amine of a lysine residue within a tumor-targeting peptide (e.g., octreotide, RGD) while preserving the cyclic peptide’s receptor affinity. The peptide is first dissolved in 0.1 M sodium borate buffer at pH 8.5, and a 1.2-fold molar excess of the SMP-chelator conjugate—pre-synthesized by reacting the chelator’s amine with SMP’s NHS ester in anhydrous dimethylformamide—is added at 4 °C with gentle shaking for 90 minutes. The product is purified by semi-preparative HPLC on a C18 column using a gradient of 0.1% TFA in water to 0.1% TFA in acetonitrile over 30 minutes, and the identity is confirmed by MALDI-TOF MS with a observed mass accuracy of <0.02%. The maleimide moiety remains intact throughout this process provided that the pH is not elevated above 9.0. Radiolabeling with ⁶⁸Ga (obtained from a ⁶⁸Ge/⁶⁸Ga generator eluted with 0.1 M HCl) is performed by mixing the peptide conjugate (20 nmol) with ⁶⁸GaCl₃ (150 MBq) in 1 M HEPES buffer at pH 4.5 for 10 minutes at 95 °C, achieving a radiochemical yield of ≥92% and a specific activity exceeding 8.5 GBq/μmol. Radiochemical purity is assessed by instant thin-layer chromatography on silica-gel impregnated glass fiber sheets developed in 0.1 M sodium citrate, and must exceed 98% per Ph. Eur. monograph 2464. A critical limitation during the conjugation step is the sensitivity of the maleimide to the reducing agents sometimes employed to generate free thiols on targeting vectors; if a thiol-containing peptide is the intended partner, the reaction must be performed under strict exclusion of residual DTT or β-mercaptoethanol traces, as these can quench the maleimide irreversibly. Stability of the final radiopharmaceutical in human serum at 37 °C is monitored by radio-HPLC, and transchelation studies using 50 mM histidine challenge show <4% demetallation over 4 hours, meeting EMA guidelines for diagnostic radiopharmaceuticals.

Crosslinking thiolated hyaluronic acid with amine-bearing gelatin to form injectable interpenetrating network hydrogels for cartilage tissue engineering

Thiolated hyaluronic acid (HA-SH) is synthesized by reacting sodium hyaluronate (200 kDa) with cystamine dihydrochloride via EDC/NHS coupling at pH 4.75, followed by DTT reduction to yield free thiol content of 180–220 μmol/g, as determined by Ellman’s spectrophotometric analysis at 412 nm. Gelatin is functionalized with amine-reactive groups by reacting with ethylenediamine in the presence of EDC to increase free amine density to 0.45 mmol/g. To fabricate the hydrogel, HA-SH is dissolved at 2.5% w/v in degassed PBS pH 6.8, and SMP is added at a maleimide-to-thiol ratio of 2:1 from a 50 mg/mL stock in dimethylacetamide; the mixture is homogenized by vortexing and immediately combined with an equal volume of 4% w/v amine-enriched gelatin solution in the same buffer. Gelation initiates within 3–5 minutes, monitored by oscillatory rheometry on a cone-and-plate geometry (1° cone, 40 mm diameter) at 1 Hz and 1% strain. The storage modulus G′ crosses over loss modulus G″ at approximately 150 seconds, and the final plateau G′ reaches 850 ± 70 Pa after 25 minutes, reflecting the contribution of SMP-mediated amide bonds between lysine residues and the NHS ester, while the maleimide-thiol linkages anchor the hyaluronic backbone. Swelling ratio in PBS at 37 °C equilibrates at 38 ± 4 after 24 hours, and enzymatic degradation by 10 U/mL hyaluronidase yields a 50% mass loss within 21 days, suitable for neo-cartilage matrix deposition. An observed processing bottleneck is the rapid hydrolysis of NHS ester in the presence of the amine-rich gelatin at pH >7.0, which can prematurely crosslink the gelatin solution before homogenous mixing is achieved; to circumvent this, the gelatin preparation is adjusted to pH 6.5 and chilled to 4 °C before mixing, extending the pot life to 10 minutes. Sterility for in vivo implantation is ensured by double filtration through 0.22 μm sterile syringe filters, and endotoxin levels are verified to be <0.25 EU/mL per USP <85> using the LAL kinetic chromogenic method.

How does the ratio of SMP to protein influence the hydrodynamic radius and inter-subunit crosslinking efficiency in multimeric vaccine presentation platforms?

When SMP is used to conjugate subunit antigens to a virus-like particle (VLP) carrier, the simultaneous presence of surface-exposed cysteine residues on the VLP and lysine residues on the antigen creates a controlled hetero-crosslinking architecture. The VLP—typically derived from bacteriophage Qβ or hepatitis B core protein—is first buffer-exchanged into 20 mM HEPES, 150 mM NaCl, pH 6.5 using a 100 kDa MWCO spin concentrator, and the free cysteine count is confirmed by Ellman’s assay; a range of 12–18 accessible thiols per VLP is common. SMP is then introduced at a maleimide-to-thiol stoichiometry of 1.5:1 to avoid bridging adjacent cysteines, and the reaction is allowed to proceed for 45 minutes at 22 °C with gentle orbital mixing at 200 rpm. After desalting on a Sephadex G-25 column equilibrated with pH 6.0 citrate buffer to retain the NHS ester, the activated VLP is immediately combined with 2.5 equivalents (relative to NHS ester) of recombinant protein antigen bearing a single exposed lysine residue at its N-terminus—engineered to avoid crosslinking of internal catalytic residues. Conjugation proceeds for 2 hours and is terminated by addition of 10 mM Tris at pH 7.5. The product is analyzed by asymmetric flow field-flow fractionation (AF4) coupled to multi-angle laser light scattering (MALLS) to determine the molar mass distribution; a shift from 2.4 MDa to 3.1 MDa corresponds to an average of 6–8 successfully conjugated antigen monomers per VLP, an optimal ratio for B-cell receptor clustering without inducing epitope masking as confirmed by ELISA against conformation-specific monoclonal antibodies. Dynamic light scattering reveals an increase in Rh from 14.2 nm to 18.7 nm with a maintained polydispersity below 0.15. An analytical-scale cation-exchange HPLC method on a Source 15S column separates conjugated, under-conjugated, and over-conjugated species, with the specification band for drug substance acceptance defined by ±1.2 standard deviations from the target peak retention volume. Stability studies at 4 °C over 12 weeks indicate that the greatest loss of structural integrity arises from hydrolysis of the succinimidyl amide bond linking antigen to VLP, with an observed 8% dissociation monitored by sandwich ELISA, within the acceptable threshold of <10% defined in ICH Q5C for biotechnological products.